Biopharma in China

Innovation, Trends and Dealmaking

Sven Agten, Ben Wu

$116.95 $93.30

Hardback

Not in-store but you can order this
How long will it take?

Availability Information

We source books from suppliers in Australia and overseas. For books we don't currently have in stock, the time it takes to get them from our suppliers can vary widely - from a few days to a few months - so we check each book with each supplier to determine the expected time it will take to be supplied to us.

We then advise you accordingly. If the time taken to get any book is too long for you, you can let us know and we will cancel or adjust your order, and refund as required.

To find out the anticipated arrival time for specific items prior to ordering, please contact us by phone or email:

Phone +61 2 9264 3111, or 1800 4 BOOKS (1800 4 26657) if outside Sydney:
option 1 Abbey's Bookshop (Crime, History, Science, Kids & more) • info@abbeys.com.au
option 2 Language Book Centre (ESL & Foreign Languages) • language@abbeys.com.au
option 3 Galaxy Bookshop (Sci-fi, Fantasy, Romance, Graphic Novels) • sf@galaxybooks.com.au

QTY:

English

Palgrave Macmillan
17 April 2024

Chemical industries; Medical research

This book provides an insider’s overview of the emerging Chinese biopharma sector, its dynamics and trends, first bust and boom cycle, long-term perspectives, and how as a foreign company or investor to tap into this. China has gone from a country with no innovation in drug discovery, to a country which starts to out-license its biopharma technology to the rest of the world. The Chinese biopharma sector is only a decade old, but it already has become a new driver of growth and value. The book takes a closer look at what drives Chinese innovation in the biopharma sector, how to deal with this innovation, and what opportunities and challenges this provides for foreign companies. The book also takes a deep dive into its first biopharma boom and bust cycle, and what it means for the sector. It also explains what deals Chinese biopharma companies and investors are looking for, what works and what doesn’t, and how as a foreign company can tap into the world’s second largest healthcare market.

By: Sven Agten, Ben Wu
Imprint: Palgrave Macmillan
Country of Publication: Singapore
Edition: 1st ed. 2024
Dimensions: Height: 210mm, Width: 148mm,
ISBN: 9789819714704
ISBN 10: 9819714702
Pages: 155
Publication Date: 17 April 2024
Audience: Professional and scholarly , Undergraduate
Format: Hardback
Publisher's Status: Active

Chapter 1: The Chinese healthcare and pharmaceutical market: Ignore at your own peril.- Chapter 2: China regulatory and legal reforms: Gateway to innovation and global integration.- Chapter 3: The golden age of the Chinese biopharma: Explosive growth in a thriving ecosystem.- Chapter 4: Innovation in the Chinese biopharma: From me-too to First-in-class.- Chapter 5: The art of the biopharma deal: The China angle.- Chapter 6: End if the first cycle. A drastic rest, future challenges and opportunities.

Ben Wu has close to 30 years of experience in the pharmaceutical industry, holding senior executive positions in the Asia Pacific region for multinationals like J&J and Sanofi. He was active in several China originated biopharma companies, and is the founding CEO of Citrine Medicine, a venture capital backed biopharma. Originally from Belgium, Sven Agten has been living and working in China since 2004. He is a seasoned business executive working for SMEs and multinationals, with in-depth experience about business in China. He has published several books about China, all related to China business challenges, trends and opportunities.